Radiprodil

About GRIN Therapeutics

GRIN Therapeutics, founded in 2020 and based in Cambridge, USA, is a private, pre-revenue biotech focused on developing small molecule therapeutics for severe pediatric neurodevelopmental disorders. The company's lead asset is radiprodil, an investigational therapy targeting dysregulated NMDA receptor activity, which is currently in a global Phase 3 trial for GRIN-NDD and being explored for other conditions like tuberous sclerosis complex. GRIN Therapeutics represents a precision medicine approach to a high-need, rare disease space with significant scientific and clinical validation potential.

About GRIN Therapeutics

GRIN Therapeutics, founded in 2020 and based in Cambridge, USA, is a private, pre-revenue biotech focused on developing small molecule therapeutics for severe pediatric neurodevelopmental disorders. The company's lead asset is radiprodil, an investigational therapy targeting dysregulated NMDA receptor activity, which is currently in a global Phase 3 trial for GRIN-NDD and being explored for other conditions like tuberous sclerosis complex. GRIN Therapeutics represents a precision medicine approach to a high-need, rare disease space with significant scientific and clinical validation potential.

About GRIN Therapeutics

GRIN Therapeutics, founded in 2020 and based in Cambridge, USA, is a private, pre-revenue biotech focused on developing small molecule therapeutics for severe pediatric neurodevelopmental disorders. The company's lead asset is radiprodil, an investigational therapy targeting dysregulated NMDA receptor activity, which is currently in a global Phase 3 trial for GRIN-NDD and being explored for other conditions like tuberous sclerosis complex. GRIN Therapeutics represents a precision medicine approach to a high-need, rare disease space with significant scientific and clinical validation potential.

Therapeutic Areas